The latest announcement is out from Zevra Therapeutics ( (ZVRA) ).
On February 26, 2025, Zevra Therapeutics entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $150 million. This transaction, expected to close within 30 to 45 days, will provide non-dilutive capital to support Zevra’s strategic priorities, including the commercial launches of MIPLYFFA and OLPRUVA and the advancement of its product pipeline.
More about Zevra Therapeutics
Zevra Therapeutics, Inc. is a commercial-stage company focused on developing and providing therapies for rare diseases with limited or no treatment options. The company employs data-driven development and commercialization strategies to address complex drug development challenges and aims to deliver life-changing therapeutics to the rare disease community.
YTD Price Performance: -15.64%
Average Trading Volume: 424,176
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $394.4M
See more insights into ZVRA stock on TipRanks’ Stock Analysis page.